TITLE

Leukotriene receptor antagonists as potential steroid sparing agents in a patient with serosal eosinophilic gastroenteritis

AUTHOR(S)
Urek, M C.; Kujundžić, M.; Banić, M.; Urek, R.; Veić, T. Š.; Kardum, D.
PUB. DATE
September 2006
SOURCE
Gut;Sep2006, Vol. 55 Issue 9, p1363
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
A letter to the editor discussing the case study of a patient suffering from serosal eosinophilic gastroenteritis who was administered leukotriene receptor antagonists as potential steroid sparing agents is presented.
ACCESSION #
22184130

 

Related Articles

  • BTS guidelines for add-on therapy 'already out of date'. Dragon, Natalie // GP: General Practitioner;3/17/2003, p10 

    Reports that research on leukotriene receptor antagonists (LTRA) has challenged asthma guidelines recommended by the British Thorasic Society. Effectiveness of LTRA to control asthma; Contribution of David Price, researcher of the Clinical Observation of Montelukast as a Partner Agent for...

  • Breathe easier. Gordon, Mary Ebitt // Self;Apr97, Vol. 19 Issue 4, p95 

    Reports on the availability of leukotriene receptor antagonists or inhibitors, oral medications for asthma sufferers. Drugs in the category introduced in the market; Need for doctor's prescription on the kind of drug suited for severity of asthma.

  • Montelukast and Dosage of Inhaled Steroids in Asthma. Walling, Anne D. // American Family Physician;11/15/1999, Vol. 60 Issue 8, p2374 

    Presents an abstract of the study `Randomised, Placebo-controlled Trial of Effect of a Leukotriene Receptor Antagonist, Montelukast, on Tapering Inhaled Corticosteroids in Asthmatic Patients,' by C.G. Lofdahl et al., which appeared on July 10, 1999 issue of the `British Medical Journal.'

  • Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Vaquerizo, M.J.; Casan, P.; Castillo, J.; Perpina, M.; Sanchis, J.; Sobradillo, V.; Valencia, A.; Verea, H.; Viejo, J.L.; Villasante, C.; Gonzalez-Esteban, J.; Picado, C. // Thorax;Mar2003, Vol. 58 Issue 3, p204 

    Examines the efficacy of adding oral montelukast, a leukotriene receptor antagonist, to a constant dose of inhaled budesonide for patients with asthma. Methods; Results; Conclusion.

  • LEUKOTRIENE RECEPTOR ANTAGONIST PRANLUKAST SUPPRESSES EOSINOPHIL INFILTRATION AND CYTOKINE PRODUCTION IN HUMAN NASAL MUCOSA OF PERENNIAL ALLERGIC RHINITIS. Ueda, Tsutomu; Takeno, Sachio; Furukido, Kyosuke; Hirakawa, Katsuhiro; Yajin, Koji // Annals of Otology, Rhinology & Laryngology;Nov2003, Vol. 112 Issue 11, p955 

    The purpose of this study was to investigate the influence of pranlukast on eosinophilic inflammation and cytokine production in human nasal mucosa. Twelve patients were treated with pranlukast, and samples were obtained from the nasal mucosa of the inferior turbinate. With respect to cell...

  • Leukotriene Receptor Antagonists.  // Encyclopedic Reference of Molecular Pharmacology;2004, p551 

    A definition of the term "leukotriene receptor antagonists" is presented. It refers to agents that inhibits the cysLT receptor and prevent the actions of leukotrines.

  • Leukotriene receptor antagonists as add-on therapy for adults with asthma. Thomson, N.C.; Shepherd, M. // Thorax;Mar2003, Vol. 58 Issue 3, p190 

    Editorial. Examines the use of leukotriene receptor antagonists as add-on therapy for adults with moderate to severe asthma. Challenges in moderate and severe persistent asthma; Recommendations from asthma guidelines on the use of leukotriene receptor antagonists; Safety of the antagonists.

  • Focus on zafirlukast: A leukotriene receptor antagonist for the prophylaxis and chronic... Baldinger, Sandra L.; Shore, Eric T. // Formulary;Nov96, Vol. 31 Issue 11, p1029 

    Examines the use and effectiveness of zafirlukast, a potent and specific leukotriene receptor antagonist approved by the Food and Drug Administration (FDA) for the treatment of asthma in patients 12 years of age and older. Chemistry and pharmacology; Pharmacokinetics; Results of clinical trials...

  • Defining the role of antileukotriene agents in the management of asthma. Johnson, Margaret M. // Formulary;Jan2000, Vol. 35 Issue 1, p38 

    The newest class of asthma medications to be marketed in the United States are the antileukotriene agents (ALAs). They include one 5-lipoxygenase inhibitor, zileuton, and two leukotriene receptor antagonists, zafirlukast and montelukast. By inhibiting the formation of cysteinyl leukotrienes or...

  • ROLE OF LEUKOTRIENE RECEPTOR ANTAGONIST MONTELUKAST IN THE TREATMENT OF CHRONIC URTICARIA: A HOSPITAL BASED STUDY. Hassan, Iffat; Bhatt, Taseer Ahmad; Altaf, Hinah; Sameem, Farah; Masood, Qazi // Our Dermatology Online / Nasza Dermatologia Online;Oct2012, Vol. 3 Issue 4, p309 

    Introduction: Chronic urticaria is a disabling disease which may be refractory to standard therapies. Leukotriene receptor antagonists like montelukast have been tried in allergic diseases like asthma and find mention as a therapeutic option in chronic urticaria. Purposes: A randomized...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics